Cargando…

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia

As one of Gavi, the Vaccine Alliance (previously the Global Alliance for Vaccines and Immunization), graduating countries, Indonesia is still eligible to access Gavi price for PCV13, PCV10 A and B. This study aims to estimate the economic impact of switch from the existing product/presentation of PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Suwantika, Auliya A., Zakiyah, Neily, Kusuma, Arif S. W., Abdulah, Rizky, Postma, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349927/
https://www.ncbi.nlm.nih.gov/pubmed/32443523
http://dx.doi.org/10.3390/vaccines8020233
_version_ 1783557168163717120
author Suwantika, Auliya A.
Zakiyah, Neily
Kusuma, Arif S. W.
Abdulah, Rizky
Postma, Maarten J.
author_facet Suwantika, Auliya A.
Zakiyah, Neily
Kusuma, Arif S. W.
Abdulah, Rizky
Postma, Maarten J.
author_sort Suwantika, Auliya A.
collection PubMed
description As one of Gavi, the Vaccine Alliance (previously the Global Alliance for Vaccines and Immunization), graduating countries, Indonesia is still eligible to access Gavi price for PCV13, PCV10 A and B. This study aims to estimate the economic impact of switch from the existing product/presentation of PCV (single-dose of PCV13) to the new product/presentation of PCV (multi-dose of PCV13, PCV10 A and B) since PCV is one of the most expensive vaccines in the Expanded Program on Immunization (EPI) schedule. Assuming that Gavi-Advance Market Commitment (AMC) price for all PCVs can be accessed in 2021, the use of multi-dose PCV13, PCV10 A and PCV10 B with Gavi-AMC price in 2021–2024 were considered as respective scenarios. The result showed that the scenario assuming the use of single-dose of PCV13 with contract price in 2019–2020 that would be switched into multi-dose of PCV10 B with Gavi-AMC price in 2021–2024 resulted in the highest potential saving, compared with other scenarios. Our analysis suggests an economic advantage to switch from single-dose into a multi-dose presentation. Vaccination coverage, vaccine price, vaccine wastage and additional Gavi-AMC vaccine costs were considered to be the most influential parameter affecting the savings in all scenarios. Applying the effectiveness of PCV13 and PCV10 A on reducing the risk for invasive pneumococcal disease (IPD), potential averted incidence of IPD in children under one year of age during 2019–2024 would be 246,164 and 105,587 in both scenarios. Despite the result confirmed that PCV13 may provide an additional benefit, a more comprehensive economic evaluation study is required to investigate further the comparison of cost-effectiveness values among all PCVs in Indonesia.
format Online
Article
Text
id pubmed-7349927
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73499272020-07-15 Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia Suwantika, Auliya A. Zakiyah, Neily Kusuma, Arif S. W. Abdulah, Rizky Postma, Maarten J. Vaccines (Basel) Review As one of Gavi, the Vaccine Alliance (previously the Global Alliance for Vaccines and Immunization), graduating countries, Indonesia is still eligible to access Gavi price for PCV13, PCV10 A and B. This study aims to estimate the economic impact of switch from the existing product/presentation of PCV (single-dose of PCV13) to the new product/presentation of PCV (multi-dose of PCV13, PCV10 A and B) since PCV is one of the most expensive vaccines in the Expanded Program on Immunization (EPI) schedule. Assuming that Gavi-Advance Market Commitment (AMC) price for all PCVs can be accessed in 2021, the use of multi-dose PCV13, PCV10 A and PCV10 B with Gavi-AMC price in 2021–2024 were considered as respective scenarios. The result showed that the scenario assuming the use of single-dose of PCV13 with contract price in 2019–2020 that would be switched into multi-dose of PCV10 B with Gavi-AMC price in 2021–2024 resulted in the highest potential saving, compared with other scenarios. Our analysis suggests an economic advantage to switch from single-dose into a multi-dose presentation. Vaccination coverage, vaccine price, vaccine wastage and additional Gavi-AMC vaccine costs were considered to be the most influential parameter affecting the savings in all scenarios. Applying the effectiveness of PCV13 and PCV10 A on reducing the risk for invasive pneumococcal disease (IPD), potential averted incidence of IPD in children under one year of age during 2019–2024 would be 246,164 and 105,587 in both scenarios. Despite the result confirmed that PCV13 may provide an additional benefit, a more comprehensive economic evaluation study is required to investigate further the comparison of cost-effectiveness values among all PCVs in Indonesia. MDPI 2020-05-18 /pmc/articles/PMC7349927/ /pubmed/32443523 http://dx.doi.org/10.3390/vaccines8020233 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Suwantika, Auliya A.
Zakiyah, Neily
Kusuma, Arif S. W.
Abdulah, Rizky
Postma, Maarten J.
Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
title Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
title_full Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
title_fullStr Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
title_full_unstemmed Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
title_short Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
title_sort impact of switch options on the economics of pneumococcal conjugate vaccine (pcv) introduction in indonesia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349927/
https://www.ncbi.nlm.nih.gov/pubmed/32443523
http://dx.doi.org/10.3390/vaccines8020233
work_keys_str_mv AT suwantikaauliyaa impactofswitchoptionsontheeconomicsofpneumococcalconjugatevaccinepcvintroductioninindonesia
AT zakiyahneily impactofswitchoptionsontheeconomicsofpneumococcalconjugatevaccinepcvintroductioninindonesia
AT kusumaarifsw impactofswitchoptionsontheeconomicsofpneumococcalconjugatevaccinepcvintroductioninindonesia
AT abdulahrizky impactofswitchoptionsontheeconomicsofpneumococcalconjugatevaccinepcvintroductioninindonesia
AT postmamaartenj impactofswitchoptionsontheeconomicsofpneumococcalconjugatevaccinepcvintroductioninindonesia